

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dexcel Pharma Technologies Ltd.</u> _____ (Last) (First) (Middle) 21 NAHUM HAFTZADI STREET _____ (Street) JERUSALEM L3 9548402 _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Roivant Sciences Ltd. [ROIV]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/22/2022	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	04/22/2022		P		31,685 ⁽¹⁾	A ⁽¹⁾	\$3.8289 ⁽²⁾⁽⁴⁾	98,840,843	D	
Common Shares	04/25/2022		P		8,600 ⁽¹⁾	A ⁽¹⁾	\$3.9111 ⁽³⁾⁽⁴⁾	98,849,443	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person*
Dexcel Pharma Technologies Ltd.

 (Last) (First) (Middle)
 21 NAHUM HAFTZADI STREET

 (Street)
 JERUSALEM L3 9548402

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Dexxon Holdings Ltd.

 (Last) (First) (Middle)
 1 DEXCEL STREET

 (Street)
 OR AKIVA L3 3060000

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Oren Dan

 (Last) (First) (Middle)
 1 DEXCEL STREET

 (Street)

OR AKIVA L3 3060000

(City) (State) (Zip)

Explanation of Responses:

1. Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
2. The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from \$3.685 to \$3.88.
3. The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from \$3.825 to \$3.99.
4. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

/s/ Dexcel Pharma
Technologies Ltd. by Dan
Oren, Executive Chairman 04/26/2022

/s/ Dexxon Holdings Ltd. by
Dan Oren, Director 04/26/2022

/s/ Dan Oren 04/26/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.